{"success":true,"data":{"pressRelease":{"id":"169721","rtpr_id":"nGNE7mz53W-20261015","ticker":"OSE","exchange":"Euronext Paris","all_tickers":["OSE"],"title":"REG-OSE Immunotherapeutics to Present at Chardan’s 10th Annual Healthcare Conference","author":"Globe Newswire","published_at":"2026-10-15T05:30:00.060Z","article_body":"Nantes, France, October 15, 2026 – 7:30am CEST – OSE Immunotherapeutics SA\n(ISIN: FR0012127173; Mnemo: OSE), a clinical-stage biotech company dedicated\nto developing first-in-class therapies in immuno-oncology and\nimmuno-inflammation, today announced that management will present at the\nupcoming Chardan’s 10(th) Annual Healthcare Conference held on October 20,\n2026, in New York (United States).\n\nChardan’s 10(th) Annual Healthcare Conference\nTuesday October 20, 2026\nThe Lotte New York Palace, New York, USA\n\nMarc Le Bozec, Chief Executive Officer, will participate in a fireside chat at\n1.15pm ET (7.15pm CEST).\nManagement will also hold investor meetings during the conference.\n\nABOUT OSE IMMUNOTHERAPEUTICS\nOSE Immunotherapeutics is a biotech company dedicated to developing\nfirst-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I)\nthat address the unmet patient needs of today and tomorrow. We partner with\nleading academic institutions and biopharmaceutical companies in our efforts\nto develop and bring to the market transformative medicines for people with\nserious diseases. OSE Immunotherapeutics is based between Nantes and Paris and\nis listed on Euronext. Additional information about OSE Immunotherapeutics\nassets is available on the Company’s website: www.ose-immuno.com. Follow us\non LinkedIn\n(https://www.globenewswire.com/Tracker?data=Jv_cYairHbTtA7jB58Z6iJhdFPvRQrFUUO7RouwDVLviX3DaLJNemDEqbsLY1y4VxAJBz8R28L_XhQi_LIHMAtJvtUu_yR1jJ2KklC_swDFusyssZoZE6xxlM1lwEDDVVxW0RI4cqD4ceBekFKOl4A==).\n\nContacts\n\nOSE Immunotherapeutics: investors@ose-immuno.com\n\nFP2COM (Media Relations): Florence\nPortejoie: fportejoie@fp2com.fr I +33 6 07 768 283\n\nAstr Partners (Investor Relations):\n\nUnited States: Brian Korb: brian.korb@astrpartners.com I +1 917-653-5122\n\nForward-looking statements\nThis press release contains express or implied information and statements that\nmight be deemed forward-looking information and statements in respect of OSE\nImmunotherapeutics. They do not constitute historical facts. These information\nand statements include financial projections that are based upon certain\nassumptions and assessments made by OSE Immunotherapeutics’ management\nconsidering its experience and its perception of historical trends, current\neconomic and industry conditions, expected future developments and other\nfactors they believe to be appropriate. \n\nThese forward-looking statements include statements typically using\nconditional and containing verbs such as “expect”, “anticipate”,\n“believe”, “target”, “plan”, or “estimate”, their declensions\nand conjugations and words of similar import. Although the OSE\nImmunotherapeutics management believes that the forward-looking statements and\ninformation are reasonable, the OSE Immunotherapeutics’ shareholders and\nother investors are cautioned that the completion of such expectations is by\nnature subject to various risks, known or not, and uncertainties which are\ndifficult to predict and generally beyond the control of OSE\nImmunotherapeutics. These risks could cause actual results and developments to\ndiffer materially from those expressed in or implied or projected by the\nforward-looking statements. These risks include those discussed or identified\nin the public filings made by OSE Immunotherapeutics with the AMF. Such\nforward-looking statements are not guarantees of future performance. This\npress release includes only summary information and should be read with the\nOSE Immunotherapeutics Universal Registration Document filed with the AMF on\nJune 4, 2026, including the annual financial report for the fiscal year 2025,\navailable on the OSE Immunotherapeutics’ website. Other than as required by\napplicable law, OSE Immunotherapeutics issues this press release at the date\nhereof and does not undertake any obligation to update or revise the\nforward-looking information or statements.\n\nAttachment\n*     EN_261015_OSE Immunotherapeutics - 2026 Chardan Healthcare Conference\nvdef\n(https://ml-eu.globenewswire.com/Resource/Download/b82228a8-c127-4c1c-9dbc-cc05fc6f35f9)","article_body_html":"","raw_payload":{"data":{"id":"nGNE7mz53W-20261015","title":"REG-OSE Immunotherapeutics to Present at Chardan’s 10th Annual Healthcare Conference","author":"Globe Newswire","ticker":"OSE","created":"2026-10-15T05:30:00.060Z","tickers":["OSE"],"exchange":"Euronext Paris","article_body":"Nantes, France, October 15, 2026 – 7:30am CEST – OSE Immunotherapeutics SA\n(ISIN: FR0012127173; Mnemo: OSE), a clinical-stage biotech company dedicated\nto developing first-in-class therapies in immuno-oncology and\nimmuno-inflammation, today announced that management will present at the\nupcoming Chardan’s 10(th) Annual Healthcare Conference held on October 20,\n2026, in New York (United States).\n\nChardan’s 10(th) Annual Healthcare Conference\nTuesday October 20, 2026\nThe Lotte New York Palace, New York, USA\n\nMarc Le Bozec, Chief Executive Officer, will participate in a fireside chat at\n1.15pm ET (7.15pm CEST).\nManagement will also hold investor meetings during the conference.\n\nABOUT OSE IMMUNOTHERAPEUTICS\nOSE Immunotherapeutics is a biotech company dedicated to developing\nfirst-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I)\nthat address the unmet patient needs of today and tomorrow. We partner with\nleading academic institutions and biopharmaceutical companies in our efforts\nto develop and bring to the market transformative medicines for people with\nserious diseases. OSE Immunotherapeutics is based between Nantes and Paris and\nis listed on Euronext. Additional information about OSE Immunotherapeutics\nassets is available on the Company’s website: www.ose-immuno.com. Follow us\non LinkedIn\n(https://www.globenewswire.com/Tracker?data=Jv_cYairHbTtA7jB58Z6iJhdFPvRQrFUUO7RouwDVLviX3DaLJNemDEqbsLY1y4VxAJBz8R28L_XhQi_LIHMAtJvtUu_yR1jJ2KklC_swDFusyssZoZE6xxlM1lwEDDVVxW0RI4cqD4ceBekFKOl4A==).\n\nContacts\n\nOSE Immunotherapeutics: investors@ose-immuno.com\n\nFP2COM (Media Relations): Florence\nPortejoie: fportejoie@fp2com.fr I +33 6 07 768 283\n\nAstr Partners (Investor Relations):\n\nUnited States: Brian Korb: brian.korb@astrpartners.com I +1 917-653-5122\n\nForward-looking statements\nThis press release contains express or implied information and statements that\nmight be deemed forward-looking information and statements in respect of OSE\nImmunotherapeutics. They do not constitute historical facts. These information\nand statements include financial projections that are based upon certain\nassumptions and assessments made by OSE Immunotherapeutics’ management\nconsidering its experience and its perception of historical trends, current\neconomic and industry conditions, expected future developments and other\nfactors they believe to be appropriate. \n\nThese forward-looking statements include statements typically using\nconditional and containing verbs such as “expect”, “anticipate”,\n“believe”, “target”, “plan”, or “estimate”, their declensions\nand conjugations and words of similar import. Although the OSE\nImmunotherapeutics management believes that the forward-looking statements and\ninformation are reasonable, the OSE Immunotherapeutics’ shareholders and\nother investors are cautioned that the completion of such expectations is by\nnature subject to various risks, known or not, and uncertainties which are\ndifficult to predict and generally beyond the control of OSE\nImmunotherapeutics. These risks could cause actual results and developments to\ndiffer materially from those expressed in or implied or projected by the\nforward-looking statements. These risks include those discussed or identified\nin the public filings made by OSE Immunotherapeutics with the AMF. Such\nforward-looking statements are not guarantees of future performance. This\npress release includes only summary information and should be read with the\nOSE Immunotherapeutics Universal Registration Document filed with the AMF on\nJune 4, 2026, including the annual financial report for the fiscal year 2025,\navailable on the OSE Immunotherapeutics’ website. Other than as required by\napplicable law, OSE Immunotherapeutics issues this press release at the date\nhereof and does not undertake any obligation to update or revise the\nforward-looking information or statements.\n\nAttachment\n*     EN_261015_OSE Immunotherapeutics - 2026 Chardan Healthcare Conference\nvdef\n(https://ml-eu.globenewswire.com/Resource/Download/b82228a8-c127-4c1c-9dbc-cc05fc6f35f9)"},"type":"article","timestamp":"2026-10-15T05:30:00.172329613Z","server_sent_at_ms":1792042200172},"received_at":"2026-10-15T05:30:00.220Z","source_url":null},"analysis":{"id":"157947","press_release_id":"169721","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"OSE Immunotherapeutics announced management will present at Chardan's 10th Annual Healthcare Conference on October 20, 2026, in New York.\n\nCEO Marc Le Bozec will participate in a fireside chat at 1:15pm ET and management will hold investor meetings during the event.\n\nThe release contains no new clinical, financial, or regulatory information; it is a routine investor-outreach notice for the clinical-stage immuno-oncology biotech.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine conference appearance -- suppress unless presentation content surfaces new clinical data."},"keyFigures":{},"namedEntities":{"people":[{"name":"Marc Le Bozec","role":"Chief Executive Officer"},{"name":"Florence Portejoie","role":"Media Relations, FP2COM"},{"name":"Brian Korb","role":"Investor Relations (US), Astr Partners"}],"products":[],"companies":[{"name":"OSE Immunotherapeutics SA","ticker":"OSE","relationship":"filer"},{"name":"Chardan","relationship":"conference host"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine conference appearance notice with no new data, results, or financial disclosures. CEO will participate in a fireside chat at Chardan's healthcare conference."},"tickerRelevance":{"others":[],"primary":"OSE"},"globalImportance":8,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"conference-appearance-notice","issuerAuthored":true}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"OSE Immunotherapeutics announced management will present at Chardan's 10th Annual Healthcare Conference on October 20, 2026, in New York.\n\nCEO Marc Le Bozec will participate in a fireside chat at 1:15pm ET and management will hold investor meetings during the event.\n\nThe release contains no new clinical, financial, or regulatory information; it is a routine investor-outreach notice for the clinical-stage immuno-oncology biotech.","key_figures":{},"named_entities":{"people":[{"name":"Marc Le Bozec","role":"Chief Executive Officer"},{"name":"Florence Portejoie","role":"Media Relations, FP2COM"},{"name":"Brian Korb","role":"Investor Relations (US), Astr Partners"}],"products":[],"companies":[{"name":"OSE Immunotherapeutics SA","ticker":"OSE","relationship":"filer"},{"name":"Chardan","relationship":"conference host"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-15T05:30:03.927Z","global_importance":8,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"conference-appearance-notice","issuerAuthored":true}},"durationMs":3698,"modelName":"glm-5.3-flashx"}}